Capmaxen 200 mg (Capmatinib) Tablets

• Capmaxen (Capmatinib) 200 mg Tablet is a targeted anticancer medicine used for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a MET exon 14 skipping alteration confirmed through an appropriate diagnostic test. This medicine works by specifically targeting abnormal MET signaling pathways that contribute to the growth, survival, and spread of cancer cells.

  Therapeutic Benefits:

  • Helps target cancer cells with MET exon 14 skipping mutations.
  • Supports precision medicine approaches in advanced lung cancer treatment.
  • May help slow tumor growth and disease progression in eligible patients.
  • Designed to interfere with abnormal cellular signaling associated with cancer development.
  • Provides a targeted treatment option for patients with specific genetic alterations.
  • Used as part of individualized oncology treatment plans under specialist supervision.
  • May contribute to improved disease control in appropriately selected patients.
  • Oral tablet formulation offers convenient administration compared with some injectable therapies. 

Active Pharmaceutical Ingredient (API):

• Capmatinib Hydrochloride equivalent to Capmatinib 200 mg

Dosage Form:

• Film-Coated Tablet

Strength:

• 200 mg per tablet

Pharmacological Category:

• Antineoplastic Agent
• Targeted Cancer Therapy
• MET (Mesenchymal-Epithelial Transition) Inhibitor

Composition Information:
Each film-coated tablet contains Capmatinib as the active ingredient, a selective MET receptor tyrosine kinase inhibitor. The formulation may also contain pharmaceutical excipients used to ensure tablet stability, integrity, and optimal drug delivery. Inactive ingredients may vary depending on manufacturing specifications and product batch.

Capmatinib is specifically developed to inhibit abnormal MET signaling pathways associated with certain types of non-small cell lung cancer, helping to reduce cancer cell proliferation and survival.

Capmaxen (Capmatinib) should be used only under the guidance and supervision of a qualified oncology specialist experienced in cancer treatment.

Recommended Adult Dose:

• The usual recommended dosage is determined by the treating physician based on the patient's clinical condition, treatment response, and overall health status.

Administration Guidelines:

• Take the tablets exactly as prescribed by your healthcare provider.
• Swallow tablets whole with a sufficient amount of water.
• Do not crush, chew, split, or dissolve the tablets.
• Can be taken with or without food.
• Try to take the medicine at the same times each day to maintain consistent drug levels.

Missed Dose:

• If a dose is missed, follow your physician's instructions.
• Do not take an extra dose to make up for a missed dose.
• Continue with the next scheduled dose as directed.

Vomiting After Dose:

• If vomiting occurs after taking the medicine, do not take an additional dose on the same day unless advised by your healthcare professional.
• Resume the next scheduled dose according to the prescribed regimen.

Dose Adjustments:

• Dosage modification may be necessary in patients who experience significant side effects.
• Treatment interruption, reduction, or discontinuation may be recommended based on clinical assessment.
• Regular monitoring may be required to evaluate treatment effectiveness and safety.

Important Usage Instructions:

• Follow all laboratory testing and monitoring schedules recommended by your healthcare provider.
• Inform your doctor about all medicines, supplements, and herbal products you are taking.
• Do not stop treatment without consulting your oncology specialist.
• Keep all follow-up appointments to ensure appropriate monitoring throughout therapy.